Based on existing publications, the predictive markers for immune checkpoint inhibitor therapy include: PD-L1 expression [17, 18], tumor mutational load [19, 20], DNA mismatch repair (MMR) deficiency [21] and CD8+ T-cell intensity [22, 23]. This evidence concerns the gene CD8A and neoplasm.